Venetoclax study in relapsed CLL using early tumor tracking
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL according to standard guidelines
- Your CLL is “active” right now—such as major weight loss, fevers/night sweats without infection, or worsening blood counts or swelling
- You’re 18 or older, and your day-to-day functioning is fairly good (ECOG 0–2)
- You can take venetoclax after a planned ramp-up period and you have a cancer doctor who will manage your care
- You can do required testing and visits, including swallowing the capsules
- Before treatment, you can complete required blood/compatibility testing (including G6PD and HLA tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This trial tests a targeted pill called venetoclax for people whose hairy cell leukemia has returned after other treatments. It aims to see if venetoclax can help control the disease and improve blood counts.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.